Dobutamine CRI

Synthetic catecholamine, strong β₁ agonist with milder β₂ and α₁ effects, no dopaminergic activity. Causes positive inotropy with modest vasodilation, increasing forward flow with relatively little change in blood pressure. First-choice inotrope for patients with measured or suspected low cardiac output in the presence of adequate left ventricular filling pressures.

Open calculator →

Clinical background

Dobutamine is the first-choice inotrope when the goal is to increase cardiac output without raising vascular tone substantially. It is most useful in patients with measured or suspected low forward flow despite adequate filling pressures, acute decompensated heart failure, post-bypass support, and refractory cardiogenic shock are the classic indications. It is not a vasopressor: if the problem is hypotension from low systemic vascular resistance, reach for norepinephrine instead.

Pharmacology

Synthetic catecholamine, strong β₁ agonist with milder β₂ and α₁ effects, no dopaminergic activity. The clinically meaningful consequences are:

• β₁ stimulation → positive inotropy and a smaller positive chronotropic effect
• β₂ stimulation → modest peripheral vasodilation
• Mild α₁ → some vasoconstriction, but β₂ usually dominates at clinical doses

Net effect: forward flow increases with relatively little change in mean blood pressure. Cardiac output rises, systemic vascular resistance falls modestly, and heart rate rises somewhat (less than with epinephrine or dopamine). This profile is exactly what is wanted in low-output states with adequate or elevated filling pressures.

Onset is within 1–2 minutes IV; the half-life is 2–3 minutes, so titration is rapid. Dobutamine is metabolized in the liver and conjugated to inactive metabolites.

Indications

Primary use cases:

• Acute decompensated congestive heart failure (low-output states, especially MMVD stage C/D in dogs)
• Cardiogenic shock with adequate filling pressures
• Hypotension during general anesthesia, particularly when a propofol or isoflurane plane has produced a low-output picture
• Bridge support before or after cardiac procedures
• Sepsis or SIRS where echocardiography or clinical signs suggest myocardial dysfunction in addition to vasodilation, typically as an add-on to norepinephrine, not a substitute

Dobutamine is the first-choice inotrope per Silverstein when augmentation of forward flow is the goal and adequate fluid resuscitation has been completed. In a general practice setting, the most common scenario is anesthetic hypotension that has not responded to lightening the plane and a fluid bolus, where the heart appears to be the limiting factor rather than vascular tone, though distinguishing the two without echocardiography is difficult, and norepinephrine is usually a safer empiric choice if the etiology is unclear.

Dosing

• Dogs, low cardiac output / acute CHF: 2–20 µg/kg/min, titrated from the low end
• Dogs. MMVD stage C (acute): 2.5 µg/kg/min, up-titrate to 10 µg/kg/min
• Dogs. MMVD stage D (end-stage refractory): 1 µg/kg/min, up-titrate every 15–30 minutes to 10–15 µg/kg/min; may combine with nitroprusside; use 12–48 hours
• Dogs, anesthesia hypotension: 5 µg/kg/min with propofol; 2–12 µg/kg/min with isoflurane
• Cats, low cardiac output / acute CHF: 1–5 µg/kg/min, titrated from the low end
• Cats, anesthesia hypotension: 2–20 µg/kg/min

Cat dosing tends to run lower than dog dosing for the same indication, and Plumb’s notes that doses above 5 µg/kg/min in cats have been anecdotally associated with seizures. Stay in the 1–5 µg/kg/min range for non-anesthetic indications in cats.

Start low and titrate every 5–10 minutes against blood pressure, heart rate, and (where available) cardiac-output or perfusion markers. Most patients responding to dobutamine will do so at 5–10 µg/kg/min.

Administration

Continuous IV infusion, the short half-life makes intermittent dosing impractical. A central line is preferred for sustained infusions but peripheral administration is acceptable when central access is not available.

Dobutamine is incompatible with alkaline solutions (the molecule is acidic), so do not co-infuse with sodium bicarbonate or furosemide. It is generally compatible with 5% dextrose, 0.9% sodium chloride, and lactated Ringer’s. Discard if the solution turns pink, this indicates oxidation.

Drug interactions

• Beta-blockers blunt the inotropic and chronotropic effects of dobutamine, patients on beta-blockers may show diminished response.
• Halogenated inhalant anesthetics (isoflurane, sevoflurane) increase arrhythmia risk during dobutamine infusion, similar to the effect with epinephrine but less dramatic.
• Tricyclic antidepressants and MAO inhibitors can potentiate cardiovascular effects.

Adverse effects

• Tachycardia, the most common dose-limiting effect; rate often rises before blood pressure does
• Premature ventricular complexes and other ventricular arrhythmias, risk increases with dose, hypokalemia, hypomagnesemia, and concurrent inhalant anesthesia
• Hypotension at higher doses, paradoxically, usually β₂-mediated vasodilation overtaking α₁ effects in volume-depleted patients
• Seizures in cats at doses above 5 µg/kg/min (anecdotal, per Plumb’s)
• Tachyphylaxis with infusions running longer than 24–48 hours, receptor down-regulation reduces clinical effect

Monitoring

• Continuous ECG, arrhythmias are common and dose-related
• Continuous or frequent blood pressure
• Heart rate trend (a 20–30% rise often precedes any change in stroke volume or output)
• Where available: cardiac output, lactate, ScvO₂
• Urine output as a perfusion marker
• Serum potassium and magnesium, correct derangements before or during infusion to limit arrhythmia risk

Weaning

Wean by reducing the rate in 1–2 µg/kg/min increments every 15–30 minutes while watching blood pressure and heart rate. Patients who have been on dobutamine for >24 hours often tolerate weaning poorly because of receptor down-regulation, plan a slower taper in those cases, and consider transitioning to oral pimobendan in heart failure patients before stopping the infusion.

Sources

• Plumb’s Veterinary Drugs, dobutamine monograph (current edition).
• Hart S, Silverstein DC. Catecholamines. In: Silverstein DC, Hopper K, eds. Small Animal Critical Care Medicine. 3rd ed. Elsevier; 2023:855–859. Chapter 147; Table 147.1.